Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPaseactivating protein-catalysed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compounds binding at each of these sites allowed exploration of two new approaches to Ras pathway inhibition by stabilising or covalently modifying the Ras:SOS complex to prevent the reloading of Ras with GTP. Initially, we identified ligands that bound reversibly to the Ras:SOS complex in two distinct sites, but these compounds were not sufficiently potent inhibitors to validate our stabilisation hypothesis. We conclude by demonstrating that covalent modification of Cys118 on Ras leads to a novel mechanism of inhibition of the SOS-mediated interaction between Ras and Raf, and is effective at inhibiting the exchange of labelled GDP in both mutant (G12C and G12V) and wild type Ras.
INTRODUCTION
Members of the Ras family of small GTPases function as simple molecular switches. Ras is transformed into its active, GTP-bound state by interaction with a guanine nucleotide exchange factor (GEF) such as SOS, which catalyses release of GDP and allows binding of the more abundant GTP. In this active conformation, Ras is recognised by a range of direct effectors such as Raf, PI3 kinase and Ral proteins, which in turn can drive proliferation, survival and metastasis. Under normal physiological conditions, the intrinsic GTPase activity of Ras hydrolyses GTP back to GDP, causing inactivation. This process is significantly accelerated by GTPase activating proteins (GAPs) which can increase the intrinsic hydrolysis rate by up to 1000-fold. Mutations in the KRAS oncogene are present in a significant proportion of human tumors. Estimates of mutation prevalence vary by tumor type, however, they are known to be particularly associated with carcinomas of the lung, colon and pancreas. 1 Aberrant KRAS signaling drives an aggressive proliferative phenotype that is resistant to therapy and results in poor prognosis. These mutations, most commonly G12D and G12V, impair the ability of Ras to hydrolyse the terminal phosphate of GTP, limit sensitivity to GAP stimulation, and result in perpetual activation of Ras pathways.
Ras may be considered the archetypal 'intractable target' in oncology. Despite its characterisation over 30 years ago, reports on agents that directly target Ras, or indeed any GTPase, are limited. 2 Most drug discovery efforts have been directed against its more tractable downstream effectors, for example inhibitors of the kinases Raf and MEK. 3 Guanine nucleotides exhibit picomolar affinity for Ras; therefore competitive binding at the nucleoside site is unlikely to be feasible, in contrast to conventional ATP mimetics in the field of kinase inhibition. It is possible that binding to Ras in an allosteric manner may promote loss of nucleotide, and indeed such a mechanism has been speculated for a reported inhibitor of the related GTPase Rac1, although no structural evidence for this is available 4 and no obvious structural opportunities exist for Ras. A small molecule which is able to bind to Ras-GDP and block SOS binding should be able to limit Ras activation. This approach to Ras inhibition via disruption of a key proteinprotein interaction has recently achieved validation by two independent groups. Sun et al. have reported a diverse array of small molecules that bind in a hydrophobic pocket located between the 2 helix of switch II (residues 60-74) and the central  sheet of KRas (G12D). 5 These were identified using an NMR-based screen of 11,000 fragments using 15 N-labelled protein, with the binding mode confirmed by co-crystallization.
Simultaneously, Maurer et al. reported structurally distinct small molecules that also bind to this pocket. 6 Again, an NMR screen of 3,300 fragments using full-length KRas4B (G12D) yielded hits whose structures in complex with KRas were confirmed by X-ray crystallography. Both approaches have demonstrated that binding at this site in the affinity range of 100s of M is sufficient to inhibit the SOS-mediated activation of KRas. Since oncogenic KRas is locked in its active GTP-bound state, it is unclear whether such a strategy that prevents activation might be efficacious in tumors harbouring mutations in KRas, although a role in those tumors with active signalling through wild type Ras is plausible. Recent publications by Ostrem et al. and Lim et al. has shown that inhibition of the GTPase activity of the KRas(G12C) mutant can be achieved by irreversible binding of cysteine-reactive small molecules. Compounds are described which react close to the nucleotide binding site at Cys12, and either allosterically control the GTP affinity of the mutant 7 or directly block the ability of GTP to bind. 8 The approach relies on this specific KRas mutation to introduce the reactive cysteine thiolate, resulting in compounds which, while selective over wild type Ras, cannot inhibit other Ras mutants and which may be susceptible to resistance.
An alternative approach to preventing Ras activation may be envisioned in which a small molecule is able to bind at the interface of the Ras:SOS complex. Conceptually, such an agent might be able to stabilise these partners, inhibiting dissociation of SOS, and so prevent reloading of Ras with GTP. In theory this avoids some of the challenges implicit in other approaches, such as nucleotide competition, requiring inhibition of larger protein-protein interfaces, or mutant specificity, and might offer a more tractable binding pocket than the relatively featureless Ras protein alone. Precedent for this approach emerges from the observation that the natural product Brefeldin A (BFA) binds to a related small GTPase, Arf, and its exchange factor, ARNO. 9 In this complex, GDP is also present, resulting in a quaternary complex where BFA is located in a hydrophobic pocket at the Arf-ARNO interface, onethird of which is contributed by ARNO and two-thirds by Arf. BFA acts as an uncompetitive inhibitor that stabilises an abortive Arf-GDP-ARNO complex resulting in inhibition of the secretory pathway in eukaryotic cells. 10 Compounds have recently been reported by Burns et al. which bind to the Ras:SOS complex and increase the rate of SOS-mediated nucleotide exchange. 11 This is the reverse of the desired effect for an oncology therapy but it is notable that a small molecule can affect this pathway.
Although there is no reported structure of KRas in complex with an exchange factor, the structure of the closely homologous isoform HRas in 1:1 complex with a catalytic domain construct of SOS is known. 12 Inhibitors of activation of KRas were our primary goal owing to the greater frequency of oncogenic mutations in KRas than for other Ras isoforms, however, molecular modelling predicted high homology to HRas in complex with SOS, so this was utilized as a surrogate. Indeed, in the previously described KRas fragment screen, inhibitors were reported to cross-react with both wild type K-and HRas. 5 We therefore sought to use the HRas:SOS binary complex to screen for potential ligands via X-ray crystallography, through a process of soaking 'cocktails' of small fragments into crystals of the complex. Such an approach has been reported in inhibitor design against the bacterial enzyme nucleoside 2-deoxyribosyltransferase.
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RESULTS
X-ray screening of a fragment library
To obtain a crystal system suitable for X-ray fragment screening, a novel co-expression construct was generated comprising a C-terminal truncated HRas ( This paper describes three distinct small molecule binding sites that were identified on the complex, summarized in Figure 1 . 
Fragment binding site A on SOS
The fragment binding site we identified on the SOS protein (site A in Fig. 1 ) is a flexible bowl-shaped pocket lined with several residues showing mobile side chains. Upon binding of 1 to the SOS site A (Fig. 2a) , no significant sidechain movements are observed relative to the unbound HRas:SOS structure (PDB 1BKD). Binding appears to be driven by aromatic ring interactions such as the edge-face interactions of the ligand thiazole with the phenyl ring of Phe890 of SOS ('Phe890S') 16 (~3.6 Å), and a -stacking conformation between His905S (~3.8 Å) and the ligand phenyl ring.
Binding of 2 in site A occurs without significant perturbation of protein side chains (Fig. 2b) . The key interaction is a hydrogen bond between the piperidine nitrogen and Asp887S (2.8 Å). The bromine atom of 2 is situated in a lipophilic pocket near His905S.
Binding of 3 at site A appears to be 'shape-driven' (Fig. 2c ). An edge-face interaction is observed between Tyr884S and the ligand phenyl (~4 Å), and a -stacking interaction between Phe890S and the triazine (~3.7 Å).
Phe890S is displaced by ~1.8 Å and rotated compared with the unbound structure 1BKD. The basic nitrogen of the ligand piperidine forms a hydrogen bond with the carboxylic acid of Asp887S (3.0 Å). Lys898S changes from a dual to a single occupancy state, moving 4.3 Å to avoid a steric clash with the methylsulfanyl group of 3, with concomitant movement of Glu902S which forms a salt bridge with Lys898S (4.0 Å).
The crystal structure solved for 4a and 4b is notable because it comprises two fragments from the same cocktail which each bind to site A only in the presence of their partner (Fig. 2d ). An NMR-derived pK D was measurable for each fragment independently, however, given the small number of shifts observed, especially for 4b, the binding sites monitored in the solution NMR experiments may not exactly coincide with that of the partnered binding observed in the crystal structure. In this structure Phe890S rotates 6.3 Å out towards solvent opening up a lipophilic pocket at the back of site A which is filled by the 4a bromine. 4b is stacked between His905S and the pyrrolidine of 4a, whilst 4a is sandwiched between Phe890S and Tyr884S, and lies perpendicular to the plane of 4b.
Binding site A corresponds to the site recently reported by Burns, et al. 11 The three X-ray crystal structures they describe (4NYI, 4NYJ, 4NYM) show minimal side chain movements in site A compared with the unbound structure of SOS, and correspond most closely with our structures of 1 and 2 in complex with HRas:SOS (Figs. 2a & 2b) . 
Fragment binding site B at the HRas:SOS interface
The binding site identified at the interface of HRas and SOS ('site B') corresponds to a site previously described in studies of uncomplexed Ras protein 5, 6 ('site 2'). However, while Ras ligands 7 and 8, which were identified in these studies, inhibit SOS-mediated nucleotide exchange by preventing the binding of SOS to Ras, the fragments 5 and 6
we identified as binding to site B interact with both Ras and SOS, and we hoped to show that this additional binding interaction may serve to stabilise the protein-protein interaction. Synthesis of analogues of 5 led to acylsulfonamide 6 (Fig. 3b) . Similar interactions are seen with Leu6R, Asp54R, and His911S. Compared with 5, the distance between Thr74R and the S=O group of 6 increases to a range no longer conducive to hydrogen bonding. Lys5R rotates and moves ~4 Å. However, most notable is the movement of Tyr71R, which flips from the position observed in the unbound structure, where it forms a tyrosine bridge with Table 1) .
X-ray crystal structures of ligands binding solely to Ras have been published since the work described in this paper was completed. 5, 6 Comparison of published crystal structures with that of the HRas:SOS:5 complex shows that site B corresponds with the relatively shallow 'binding site 2' of the published fragments 7 and 8 on KRas (Fig. 3d) .
Compound 5 interacts with HRas through its acylsulfonamide motif, while the corresponding space is left unoccupied by 7 and 8, which instead extend beyond the confines of site B and place polar groups in the spaces occupied by Tyr912S and His911S in the HRas:SOS complex. The resulting steric clash with SOS seems likely to contribute to the inhibition of nucleotide exchange that has been reported for 8.
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The challenge of obtaining biological activity
While we demonstrated binding of fragments at sites A and B by X-ray crystallography, and were able to quantify their binding affinities by NMR, this did not translate into a measurable effect on nucleotide exchange (vide infra).
This was not surprising, since we anticipated more potent compounds would be required to show functional activity.
We synthesized analogues of 1 and 5, varying both substituents of the sulfonamide. The most interesting compound identified was 6, where the site B binding pocket was expanded. We also made analogues of triazine 3, varying the heteroatoms in the triazine ring, switching the thiomethyl group, and varying the piperazine side chain. We found that the basicity of the piperazine ring was critical to maintain the high levels of solubility required for screening and crystallization at high concentrations. However, after several rounds of chemistry optimization, we were unable to improve the affinity of these hits significantly or demonstrate that such small ligands were measurably able to stabilize the Ras:SOS complex.
A growing body of literature suggests that use of a ligand which binds covalently to a protein target may offer a way to permanently deactivate protein function. 7, 8, 17, 18, 19 Considering the picomolar affinity of Ras for GDP, we
hypothesised that an irreversible inhibitor may afford the only realistic chance of inhibiting GTPase activity. We identified Cys118R in the HRas:SOS complex as a potentially reactive protein side chain proximal to the GDP binding site on HRas (site C in Fig. 1 ) and set out to discover fragments which would irreversibly bind to it. This cysteine residue is conserved between HRas and KRas. 
Irreversible binders at HRas:SOS site C
A library of 400 compounds was selected, comprising members with fragment-like properties 20 (MWt  300, cLogP 1-3, cLogD -1 to 3,  2H-bond donors,  6 H-bond acceptors,  2rings,  6 rotatable bonds and 20 heavy atoms) and potentially reactive functional groups. These were identified from reports in the literature 21 and by mining the data from an in-house glutathione reactivity assay, 22 in which compounds with half-lives in the range of 15-3000 minutes were judged to be suitably reactive. Typical chemotypes represented in the library are shown in Table 2 .
Compounds were screened by mass spectrometry, by observing the mass increase of the HRas:SOS complex following compound addition.
We selected the reactive N-ethylmaleimide (NEM) group as an ideal electrophilic 'warhead' to bind to Cys118R. Other warheads were deemed either insufficiently reactive (giving incomplete cysteine adduction) or too reactive (reaction with multiple cysteine or histidine residues on the HRas:SOS complex) to progress. Using X-ray crystal structures of the HRas:SOS:inhibitor complex to guide design, we anticipated that building constructive noncovalent binding interactions with the protein (i.e. increasing K i ) might allow replacement of the maleimide with a less reactive motif (i.e. reducing K inact ) whilst retaining overall inhibitory activity. 23 Substitution of the maleimide double bond offered the possibility of modulating the electrophilicity of the Michael acceptor warhead, once additional non-covalent interactions had been identified.
Promising hits from the mass spectrometry screen of reactive fragments included N-substituted maleimides 9
and 10. X-ray crystal structures obtained subsequently showed 9 (Fig. 4a) and 10 (Fig. 4b) binding with a distance of 1.8 Å between the ligand C-3 and the Cys118R sulfur atom, and continuous electron density, confirming that a covalent bond is formed between ligand and protein ( Supplementary Fig. 1) . Interestingly, the pyrrolidine-2,5-dione rings in 9 and 10 were observed to adopt different orientations. The C-4 atom in 10 presented an ideal vector for growing the fragment into a lipophilic channel (indicated with * in Fig. 4b) , and a set of analogues was synthesized to vary at this position. Analogues 11 and 12, which carry a meta-substituted phenyl ring at C-4, were successfully crystallized with HRas:SOS, adopting similar binding modes in which the C-4 substituent extends down a lipophilic groove adjacent to Glu942S (Fig. 4c) . With a meta-substituent effectively anchoring the pendant phenyl group in one orientation, compounds 13 and 14 were designed to probe interactions with Glu942S, via a bis-3,5-substituted ring.
Comparison of the published KRas:GDP crystal structure 4DSO and our HRas:SOS structures shows reorganization of the GDP binding pocket following association of Ras and SOS (Fig. 4d) . This reconfiguration involves Cys118R, which is otherwise buried in the interior of the KRas:GDP complex where it may be somewhat protected from electrophiles. When SOS binds to Ras and displaces GDP, the Cys118R residue is exposed to solvent, rendering it more vulnerable to reaction with 9-14. Once such a reaction has occurred, the covalently-bound fragment partly occludes the nucleotide binding site and could potentially also prevent reorganization of the Cys118R loop of Ras, thus locking the protein into the catalytically inactive Ras:SOS complex.
As we had hoped, fragments which covalently modified HRas in the crystal environment also demonstrated functional activity in preventing wild type KRas activation. Due to the spectral properties of these compounds it was not always possible to use previously-reported methods for monitoring nucleotide exchange with MANT-labeled GDP 6 as many of the compounds interfered with the excitation/emission spectra. Therefore, a novel homogeneous time-resolved fluorescence (HTRF) assay was designed to profile this series. In this homogenous assay, biotinKRas:GDP was labeled with streptavidin europium and GST-Raf was labeled with anti-GST XL665. Activation of KRas was initiated with the addition of SOS and GTPS. Upon binding of the active GTPS-bound streptavidin:biotin-KRas to Raf-GST:Anti-GST XL665, the europium donor and XL665 acceptor are brought into close proximity resulting in an increased acceptor emission at 665 nm (Supplementary Fig. 2 ).
Compounds 10-14 were pre-incubated with either KRas:GDP, SOS alone or a KRas:GDP:SOS mixture for 2.5
hours to allow the compound to react, then inactivated by the addition of dithiothreitol (DTT). All samples were then made up to contain the same concentrations of KRas:GDP and SOS, and incubated with streptavidin-europium for 4
hours. In a separate reaction GST-Raf was incubated with anti-GST XL665. The exchange reaction was initiated by the addition of GTPS and GST-Raf. The activation of KRas was then monitored via HTRF between the streptavidin-europium and XL665 upon binding of active KRas to GST-Raf.
Complete inhibition of KRas activation was achieved only when 10-14 were pre-incubated with KRas:GDP:SOS (Fig. 5) , which supports the hypothesis that Cys118R becomes more accessible during the conformational changes which occur during SOS-mediated nucleotide exchange. Neither pre-incubation of 11-13
with KRas:GDP with subsequent addition of SOS nor pre-incubation with SOS followed by addition of KRas:GDP led to significant inhibition of the Ras-Raf interaction. A modest degree of KRas inhibition (~40-50%) was observed when 10 and 14 were pre-mixed with KRas alone. This may be due to the increased reactivity of the Michael acceptors in these molecules causing them to behave in a less specific manner, as we had observed during the initial irreversible fragment screening campaign; 10 is an unsubstituted maleimide and 14 has two strong electron withdrawing groups on its phenyl ring. The inhibitory effects of 10-14 could be eliminated by the addition of DTT (1 mM) during the pre-incubation step, presumably because DTT reacted with the maleimide warhead before it was able to irreversibly modify the KRas:SOS complex. Site C irreversible binders show time-dependent inhibitory activity against both wild type and mutant KRas
The inactivation of wild type KRas, KRas(G12V) and KRas(G12C) was monitored using a MANT-dGDP assay and a fluorescence assay-compatible compound, 12. Initially, the KRas constructs were pre-equilibrated with MANTdGDP to replace the bound unlabelled nucleotide which co-purifies with KRas. All three constructs then underwent SOS-mediated nucleotide exchange which resulted in an increase in fluorescence upon MANT-dGDP binding. At equilibrium, the reaction cycled between the MANT-dGDP and the unlabelled nucleotide. Upon the addition of 12 (200 M), time dependent inactivation of each of the KRas constructs was observed (Fig. 6 ). An excess amount of unlabelled GDP was included as a control to compete with the MANT-dGDP resulting in a loss of fluorescence.
Since the rate of reduction of fluorescence is similar with the addition of either excess GDP or irreversible inhibitor 12, this supports the hypothesis that nucleotide exchange is driven in both cases by the rate of association of Ras:SOS. If excess GDP is present, SOS associates with Ras, the MANT-dGDP is displaced, and is then replaced with unlabelled GDP when SOS dissociates. If 12 is present when SOS associates with Ras and displaces MANTdGDP, the resulting KRas:SOS, KRas(G12V):SOS or KRas(G12C):SOS complex reacts with the irreversible inhibitor at Cys118R, forming a dead-end complex which prevents the subsequent re-binding of MANT-dGDP. 
DISCUSSION AND CONCLUSIONS
Our work with non-covalent fragments showed that it was possible to characterize compounds from multiple series binding on SOS and at the HRas:SOS interface, however, none of these compounds were sufficiently potent to show functional activity in the Ras:Raf HTRF assay. Synthesis of analogues of 1, 3, 5 and 6 led to compounds with similar binding affinities to the parent fragments and unproductive SAR. The report by Burns et al. that small molecules which bind at SOS site A cause an increase in the rate of SOS-mediated nucleotide exchange 11 was not corroborated by experiments with our fragments, suggesting that more dramatic changes or hybridization of series may be required to achieve sufficient binding affinity. While we were not able to detect functional biological activity for the probes identified at sites A and B, we believe that our observations of specific ligandable 24 interaction points may suggest a potential way forward using larger molecules such as macrocycles 25 or constrained peptides. 26 The distance between the closest atoms on non-covalent fragments bound in sites A and B is 9.1 Å. Precedent for linking distant fragment sites suggests that connecting two weak fragments can bring very large increases in potency, but is most likely to succeed when fragments are significantly closer together than sites A and B. If fragment ligands for sites A and B could be iteratively grown towards each other, however, this strategy may be more likely to succeed. 27 While our efforts to inhibit Ras by stabilization of the Ras:SOS complex by fragments binding in a reversible manner were unsuccessful, we showed that reactive fragments which covalently modify site C near to the nucleotide binding site were effective Ras inhibitors. We demonstrated complete inhibition of KRas:SOS functional activity following reaction of maleimides 10-14 with Cys118R, a previously undescribed method of inhibition of Ras. A synthetic chemistry campaign led to fragments which showed a consistent binding mode at site C, and resulted in inhibition of wild type KRas in a novel HTRF assay measuring the Ras-GTP:Raf interaction. Several potential vectors were identified for further growth of these inhibitors; for example, along the lipophilic channel from the meta position of phenyl groups in 11-14, or from the maleimide N-substituent towards SOS.
An important objective for a covalent approach to Ras:SOS inhibition is to reconcile the need to measure variations in potency of molecules -and hence structure-activity relationships -with the requirement for a warhead of high reactivity necessary to observe any inhibitory activity. With the fragment series based on maleimides, although it was possible to measure potency and inhibition of nucleotide exchange, this measure was driven largely by K inact , and small changes in K i were difficult to detect. The determination of K i changes is important to assist the design of more potent, but less reactive inhibitors. Tuning the reactivity of the covalent modifier by modulating the electrophilicity of the Michael acceptor warhead could potentially be achieved by using an electron-donating linker such as ether or amine. Kathman et al. recently published an example of this approach being used successfully against a cysteine protease. 28 Our work has explored three small molecule binding sites on the Ras:SOS complex, and details synthetically accessible small molecule probes that bind at each site. We demonstrated inhibition of KRas functional activity with compounds which bind irreversibly at site C, and showed that covalent binding with HRas in a protein crystal environment translates to nucleotide exchange inhibition in the more oncology disease-relevant isoform KRas.
Furthermore, this mechanism of KRas inactivation appears to be applicable to mutant forms of KRas which also share a Cys118 residue, such as KRas(G12C) and KRas(G12V). Although significant work remains to optimize the biological activity of the compounds we have described at site C, our discoveries open the way to a new strategy to target aberrant Ras signalling by intervening in the SOS-mediated activation of Ras. 
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